Association Between Administration of Hepatitis B Vaccine at Birth and Completion of the Hepatitis B and 4:3:1:3 Vaccine Series

Yusuf, Hussain

doi:10.1001/jama.284.8.978

Cited by 82 publications

(57 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, completion of the hepatitis B vaccination series is more likely among those receiving the first dose at birth. 22 Midwives in this study had overall confidence in the neonatal hepatitis B vaccine's safety, although more than one-third believed that the vaccine was given too young. In addition, their concern about concurrent immunisation has implications for how midwives would support additions to the infant schedule.…”

Section: Discussionmentioning

confidence: 77%

Immunisation attitudes, knowledge and practices of health professionals in regional NSW

Leask¹,

Quinn²,

Macartney³

et al. 2008

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 77%

Immunisation attitudes, knowledge and practices of health professionals in regional NSW

Leask¹,

Quinn²,

Macartney³

et al. 2008

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

“…12 Hepatitis B vaccination in the hospital increases the likelihood that a child will complete the recommended 3-dose hepatitis B vaccine series. 13 Also, beginning with the 2002 harmonized immunization schedule, approved by the ACIP, AAP, and the American Academy of Family Practitioners, a preference is stated for the first dose to be administered soon after birth. 14 The overall 76.2% infant hepatitis B vaccination rate seen in this study is slightly lower than the 81% found in a 1996 survey (New Hampshire unpublished data 1996).…”

Section: Discussionmentioning

confidence: 99%

Assessment of Perinatal Hepatitis B and Rubella Prevention in New Hampshire Delivery Hospitals

Bascom

Miller²,

Greenblatt³

2005

Pediatrics

View full text Add to dashboard Cite

ABSTRACT.Objective. To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.Methods. Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals. Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.Results. Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high. Hepatitis B vaccine birth dose was administered to 76.2% of all infants. All infants who were born to hepatitis B surface antigenpositive mothers also received hepatitis B immune globulin. Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination. The proportion of infants who were vaccinated in January and February 2000 (48.5% and 67.5%, respectively) was less than any other months, whereas the proportion who were vaccinated in December 2000 (88.2%) was the highest. Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%). In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.Conclusion. This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement. Pediatrics 2005;115:e594-e599. URL: www.pediatrics.org/ cgi

show abstract

“…17 Apart from providing early protection against the establishment of HBV infection in infants, the use of a birth dose has been associated with increased rates of individuals who actually complete the vaccination schedule. 18,19 Furthermore, an early booster dose between 4-5 years may increase the number of children with sero-protection. 16 Since the introduction of HBV vaccination in the EPI programme in 2002 in Ghana, few studies to evaluate the development of sero-protection against HBV infections in infants have been done 11,20 , and the manufacturers of the supply of vaccines have been changed a number of times.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B virus surface antigen and antibody markers in children at a major paediatric hospital after the pentavalent DTP-HBV-Hib vaccination

Apiung

Ndanu

Mingle

et al. 2017

Ghana Medical Journal

View full text Add to dashboard Cite

SUMMARY Objectives:The knowledge about outcomes of infant vaccination against HBV infections using the DPT-HepB-Hib vaccine in Ghana is limited. This study therefore investigated the levels of immunity to HBV among children who received the DPT-HepB-Hib vaccine and HBsAg carriage in non-responders. Correlates for non-response or poor response were also investigated. Methods: Cross-sectional study. A major paediatric hospital in Accra. Four hundred and twenty four children between the ages of 5 to 32 months who had completed the full vaccination schedule for the DPT-HepB-Hib vaccine. Results: Of the 424 children, 358 (84.4%) developed anti-HBs while 340 (80.2%) developed ≥10 mIU/ml anti-HBs (sero-protection) and 3 had HBsAg. A binary logistic regression analysis showed that younger children were associated with sero-conversion (p=.022) and sero-protection (p=.021). For anti-HBs titres ≥100 mIU/ml age was a weaker but significant contributor (p=.041), as compared to the number of vaccines from different manufacturers the child used (p=.028). The mean age of those who used a single type of vaccine was higher (14.75 ± 6.056 months; n=268) than those who used vaccines from two or more manufacturers (11.96 ± 4.645 months; n=156), p= <.001 (CI: -3.897 -1.688), an indication that efforts to procure vaccine from same source when it was initially introduced are waning. Conclusions: There is still a residual possibility of infection with HBV in spite of infant vaccination. In the light of possible loss of anamnestic response over time, there is the need to consider a birth dose for HBV vaccination for all neonates or booster dose for infants who may not have received the vaccine at birth. Using vaccines from a single manufacturer is recommended. Funding: None declared

show abstract

Association Between Administration of Hepatitis B Vaccine at Birth and Completion of the Hepatitis B and 4:3:1:3 Vaccine Series

Abstract: Administration of the first dose of hepatitis B vaccine at birth is associated with increased likelihood of completion of the hepatitis B vaccination series. JAMA. 2000;284:978-983

Cited by 82 publications

References 15 publications

Immunisation attitudes, knowledge and practices of health professionals in regional NSW

Immunisation attitudes, knowledge and practices of health professionals in regional NSW

Assessment of Perinatal Hepatitis B and Rubella Prevention in New Hampshire Delivery Hospitals

Hepatitis B virus surface antigen and antibody markers in children at a major paediatric hospital after the pentavalent DTP-HBV-Hib vaccination

Contact Info

Product

Resources

About